INVO Bioscience, Inc.
INVO
$2.07
$0.239913.11%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.84M | 1.58M | 1.38M | 974.90K | 315.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.84M | 1.58M | 1.38M | 974.90K | 315.90K |
| Cost of Revenue | 861.60K | 850.20K | 886.80K | 581.00K | 235.70K |
| Gross Profit | 974.90K | 726.10K | 495.00K | 393.90K | 80.20K |
| SG&A Expenses | 2.65M | 1.44M | 1.86M | 1.26M | 2.04M |
| Depreciation & Amortization | 230.30K | 227.00K | 141.60K | 20.50K | 19.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.74M | 2.52M | 2.89M | 1.86M | 2.38M |
| Operating Income | -1.90M | -946.40K | -1.51M | -886.30K | -2.07M |
| Income Before Tax | -2.25M | -1.59M | -1.97M | -1.25M | -2.24M |
| Income Tax Expenses | -- | 1.80K | 23.00K | 1.90K | 2.90K |
| Earnings from Continuing Operations | -2.25M | -1.60M | -1.99M | -1.25M | -2.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.25M | -1.60M | -1.99M | -1.25M | -2.24M |
| EBIT | -1.90M | -946.40K | -1.51M | -886.30K | -2.07M |
| EBITDA | -1.67M | -719.40K | -1.37M | -865.80K | -2.05M |
| EPS Basic | -0.62 | -0.42 | -0.64 | -0.70 | -3.06 |
| Normalized Basic EPS | -0.39 | -0.19 | -0.34 | -0.44 | -1.91 |
| EPS Diluted | -0.62 | -0.42 | -0.64 | -0.70 | -3.06 |
| Normalized Diluted EPS | -0.39 | -0.19 | -0.34 | -0.44 | -1.91 |
| Average Basic Shares Outstanding | 3.61M | 3.80M | 3.12M | 1.78M | 732.30K |
| Average Diluted Shares Outstanding | 3.61M | 3.80M | 3.12M | 1.78M | 732.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
